SYMLIN

LOE Approaching

pramlintide acetate

NDASUBCUTANEOUSINJECTABLE
Approved
Mar 2005
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
5

Mechanism of Action

amylin. Amylin is colocated with insulin in secretory granules and cosecreted with insulin by pancreatic beta cells in response to food intake. Amylin and insulin show similar fasting and postprandial patterns in healthy individuals (Figure 1). Figure 1: Secretion Profile of Amylin and Insulin in…

Clinical Trials (5)

NCT01841359Phase 4Completed

Pramlintide (Symlin) for the Treatment of Hypoglycemia Following Gastric Bypass Surgery

Started Feb 2010
22 enrolled
HypoglycemiaEvidence of Previous Gastric Surgery
NCT00467649Phase 4Completed

A Study to Characterize Regimens of Basal Insulin Intensified With Either Symlin® or Rapid Acting Insulin in Patients With Type 2 Diabetes

Started May 2007
112 enrolled
Type 2 Diabetes Mellitus
NCT00313183Phase 2Completed

A Study to Evaluate Symlin in Adolescent Subjects With Type 1 Diabetes Mellitus

Started Apr 2006
12 enrolled
Type 1 Diabetes Mellitus
NCT00240253Phase 4Completed

A Study Evaluating the Efficacy and Safety of Adding Symlin® to Lantus® (Insulin Glargine) in Subjects With Type 2 Diabetes

Started Oct 2005
200 enrolled
Type 2 Diabetes Mellitus
NCT00229658N/ACompleted

An Observational Study Evaluating SYMLIN® (Pramlintide Acetate) Injection Use in Insulin Using Patients With Type 2 and Type 1 Diabetes

Started Sep 2005
1,297 enrolled
Type 1 Diabetes MellitusType 2 Diabetes Mellitus
Data Sources
  • Drug label: DailyMed / FDA
  • Clinical trials: ClinicalTrials.gov
  • Patent data: FDA Orange Book
  • Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.